|  |  | 

India Top Headlines

AIIMS Delhi Starts Screening of Children for Covaxin Trials | India News


NEW DELHI: Child screening for the trial of Covaxin, India’s first indigenously developed Covid-19 vaccine, among children ages 2 to 18 began at AIIMS on Monday. The trial in children has already started at AIIMS Patna to see if the Bharat Biotech jab is suitable for children.
Participants will receive the vaccine after their screening report arrives. The trial will be carried out with 525 healthy volunteers. In the trial, the vaccine will be administered intramuscularly in two doses on day 0 and day 28.
“Screening of children for a Covaxin trial has begun. Participants would receive the vaccine after their screening reports came in,” said Dr. Sanjay Rai, a professor at the AIIMS Center for Community Medicine.
India’s drug regulator had granted permission to conduct the phase 2/3 clinical trial of Covaxin in the age group 2-18 years on May 12.
Covaxin is being used in adults in India’s ongoing Covid-19 vaccination campaign. Last week, the government warned that although Covid-19 has not taken a serious form among children so far, its impact may increase among them if there is a change in the behavior of the virus or epidemiological dynamics, and said that they are being strengthening preparations to face any problem. such a situation.
A group of national experts has been formed to review Covid-19 infections in children and address the pandemic in a renewed way to strengthen the nation’s preparedness, NITI member Aayog (Health) VK Paul said at a press conference. .
The group has examined signals that weren’t available four to five months earlier, he said.
It has also considered the available data, the clinical profile, the country experience, the dynamics of the disease, the nature of the virus and the pandemic and has developed guidelines, which will be released to the public soon.
“While we have been systematically reviewing scientific developments in this area, the group has been formed to get an up-to-date view of the situation,” Paul said.
When asked if the Pfizer vaccine, if it reaches India, will be considered for children aged 12-15 as approved by the UK, Paul said the country has its own vaccines that are being prepared for children.
“The cohort of children is not a small cohort. My rough guess is that if you are between 12 and 18 years old, this itself is a population of 13 to 14 crore and for which we will need between 25 and 26 crore doses.” We cannot have some people receive and others do not. Therefore, we will need to take this into account when strategizing and making a decision based on the number of doses of available vaccines. he said.
In addition, he shared that the Zydus Cadila vaccine is already being tested in children.
“So when Zydus comes in to get licensed, hopefully in the next two weeks, we may have enough data to assess whether the vaccine can be given to children,” he said.

Times of India